Paracrine
Paracrine develops regenerative therapies for chronic wound care, leveraging autologous cell-based treatments and real-time AI platforms to enhance healing precision, predictability, and efficiency. The company operates globally, focusing on scalable and cost-effective biological solutions that integrate advanced machine learning for improved patient outcomes.
Patents
Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen
2023-04-25 • US-11633382-B2
View DetailsMethod of deriving mesenchymal stem cells from ES cells using FGF2
2015-02-24 • US-8962318-B2
View Details
Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen
2023-04-25 • US-11633382-B2
View DetailsMethod of deriving mesenchymal stem cells from ES cells using FGF2
2015-02-24 • US-8962318-B2
View DetailsWhat We Do
Autologous cell-based therapy for chronic wound healing, using regenerative cells from the patient's own adipose tissue.
Suite of AI-powered software modules supporting clinical decision-making, patient monitoring, and outcome prediction for regenerative wound therapies.
Autologous cell-based therapy for chronic wound healing, using regenerative cells from the patient's own adipose tissue.
Suite of AI-powered software modules supporting clinical decision-making, patient monitoring, and outcome prediction for regenerative wound therapies.